Ukrainian pharmaceutical manufacturer with EU research experience in drug formulation, nanocarrier delivery systems, and biopharmaceutics technology transfer.
FARMAK is an established Ukrainian pharmaceutical manufacturer that contributes industrial drug development and formulation expertise to European research consortia. Their core work spans the pharmaceutical development pipeline — from nanocarrier design and molecular target studies through to dosage form development, processability testing, biorelevant dissolution analysis, and technology transfer into production. Through MSCA-RISE participation, they operate as an industrial host site for researcher exchanges, bridging academic pharmaceutical science with real manufacturing practice. This positions them as an industry-grounded partner for research teams that need access to applied pharmaceutical technology infrastructure rather than purely academic laboratory capacity.
VAHVISTUS (2017–2022) centred on designing smart drug-vector nanostructures for adaptive delivery to target cells, with FARMAK contributing pharmaceutical expertise on nanocarrier development and active compound selection.
ORBIS (2018–2023) lists preformulation, pharmaceutical technology, dosage forms, and processability as core keywords, reflecting FARMAK's industrial formulation capabilities.
ORBIS keywords include biorelevant dissolution, biomedical analysis, and biopharmaceutics — analytical and characterisation methods that are standard in industrial pharmaceutical quality and development labs.
ORBIS explicitly lists technology transfer as a keyword, consistent with an industrial partner helping research outputs cross the gap into scalable pharmaceutical production.
VAHVISTUS involved intracellular parasite targeting via the secretory pathway and molecular docking, indicating exposure to anti-parasitic pharmaceutical research beyond standard formulation work.
In their first project (VAHVISTUS, started 2017), FARMAK's contributions aligned with foundational drug delivery science — nanocarrier engineering, molecular docking, intracellular parasite biology, and secretory pathway mechanisms, suggesting engagement with discovery-stage and translational research. By their second project (ORBIS, started 2018), the keyword profile shifted decisively toward applied pharmaceutical development: preformulation, biorelevant dissolution, processability, and technology transfer — the vocabulary of an industrial development lab preparing formulations for scale-up. The trajectory is clear: from upstream biology-adjacent nanocarrier science toward the downstream, manufacturing-oriented pharmaceutical development skills that define their day-to-day industrial work.
FARMAK is orienting toward the applied pharmaceutical development and industrialisation skills — formulation science, dissolution testing, technology transfer — that reflect the practical needs of a manufacturer rather than a research institute, making them an increasingly useful partner for projects that need to move from compound to dosage form.
FARMAK has participated exclusively as a consortium partner across both projects, never as coordinator, which is the standard industrial role in MSCA-RISE schemes where companies contribute by hosting and exchanging researchers rather than setting scientific agendas. Their 19 unique partners across 11 countries in just two projects signals membership in large, well-networked multi-institutional consortia. As an industrial MSCA-RISE host, working with them typically means gaining access to a functioning pharmaceutical manufacturing and development environment for researcher placements rather than a co-PI scientific relationship.
Despite being based outside the EU, FARMAK has established connections with 19 consortium partners across 11 countries through two MSCA-RISE projects, indicating genuine integration into broad European pharmaceutical research networks. Their non-EU location adds geographic diversity that is structurally valuable for staff exchange consortia needing international breadth.
As a non-EU pharmaceutical manufacturer with verified H2020 participation, FARMAK offers industrial pharmaceutical infrastructure that is geographically distinct from typical Western European partners — a practical asset for MSCA-RISE consortia that need international third-country participants. They combine documented expertise in formulation science and biopharmaceutics with an operating manufacturing environment, making them more than a nominal affiliate: researchers placed there work in a real production-oriented pharmaceutical setting. For teams building pharmaceutical or drug delivery consortia that need an industrial Eastern European partner with credible EU research credentials, FARMAK is a specific and substantiated option.
